Cargando…
Plerixafor for autologous CD34(+) cell mobilization
High-dose chemotherapy and autologous transplantation of hematopoietic cells is a crucial treatment option for hematologic malignancy patients. Current mobilization regimes often do not provide adequate numbers of CD34(+) cells. The chemokine receptor CXCR4 and ligand SDF-1 are integrally involved i...
Autores principales: | Salman, Huda, Lazarus, Hillard M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065558/ https://www.ncbi.nlm.nih.gov/pubmed/21468240 http://dx.doi.org/10.2147/CE.S7801 |
Ejemplares similares
-
Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update
por: Bilgin, Yavuz M
Publicado: (2021) -
Day -1 CD34+ Cells and Platelet Count Predict the Number of Apheresis in Poor-Mobilizer Patients Rescued by Plerixafor
por: Valentini, Caterina Giovanna, et al.
Publicado: (2023) -
Plerixafor
por: Slater, Susan
Publicado: (2012) -
Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update [Corrigendum]
Publicado: (2022) -
Safety and efficacy of plerixafor dose escalation for the mobilization of CD34(+) hematopoietic progenitor cells in patients with sickle cell disease: interim results
por: Boulad, Farid, et al.
Publicado: (2018)